Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study

INTRODUCTION: Psoriasis is a chronic inflammatory skin disease. Adalimumab is an effective but previously expensive biological treatment for psoriasis. The introduction of biosimilars following the patent expiry of the originator adalimumab Humira has reduced the unit cost of treatment. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Phan, Duc Binh, Jourdain, Hugo, González-Quesada, Alicia, Zureik, Mahmoud, Rivera-Díaz, Raquel, Sahuquillo-Torralba, Antonio, Descalzo-Gallego, Miguel Angel, Lunt, Mark, Garcia-Doval, Ignacio, Sbidian, Emilie, Warren, R B, Yiu, Zenas Z N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351260/
https://www.ncbi.nlm.nih.gov/pubmed/37451726
http://dx.doi.org/10.1136/bmjopen-2023-075197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351260/
https://www.ncbi.nlm.nih.gov/pubmed/37451726
http://dx.doi.org/10.1136/bmjopen-2023-075197

Ejemplares similares